
Arovella Therapeutics Ltd
ASX:ALA

Arovella Therapeutics Ltd?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.07
0.205
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Arovella Therapeutics Ltd hold over its rivals?
What risks and challenges
does Arovella Therapeutics Ltd face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Arovella Therapeutics Ltd.
Provide an overview of the primary business activities
of Arovella Therapeutics Ltd.
What unique competitive advantages
does Arovella Therapeutics Ltd hold over its rivals?
What risks and challenges
does Arovella Therapeutics Ltd face in the near future?
Has there been any significant insider trading activity
in Arovella Therapeutics Ltd recently?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Arovella Therapeutics Ltd.
Provide P/S
for Arovella Therapeutics Ltd.
Provide P/E
for Arovella Therapeutics Ltd.
Provide P/OCF
for Arovella Therapeutics Ltd.
Provide P/FCFE
for Arovella Therapeutics Ltd.
Provide P/B
for Arovella Therapeutics Ltd.
Provide EV/S
for Arovella Therapeutics Ltd.
Provide EV/GP
for Arovella Therapeutics Ltd.
Provide EV/EBITDA
for Arovella Therapeutics Ltd.
Provide EV/EBIT
for Arovella Therapeutics Ltd.
Provide EV/OCF
for Arovella Therapeutics Ltd.
Provide EV/FCFF
for Arovella Therapeutics Ltd.
Provide EV/IC
for Arovella Therapeutics Ltd.
Show me price targets
for Arovella Therapeutics Ltd made by professional analysts.
What are the Revenue projections
for Arovella Therapeutics Ltd?
How accurate were the past Revenue estimates
for Arovella Therapeutics Ltd?
What are the Net Income projections
for Arovella Therapeutics Ltd?
How accurate were the past Net Income estimates
for Arovella Therapeutics Ltd?
What are the EPS projections
for Arovella Therapeutics Ltd?
How accurate were the past EPS estimates
for Arovella Therapeutics Ltd?
What are the EBIT projections
for Arovella Therapeutics Ltd?
How accurate were the past EBIT estimates
for Arovella Therapeutics Ltd?
Compare the revenue forecasts
for Arovella Therapeutics Ltd with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Arovella Therapeutics Ltd and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Arovella Therapeutics Ltd against its competitors.
Analyze the profit margins
(gross, operating, and net) of Arovella Therapeutics Ltd compared to its peers.
Compare the P/E ratios
of Arovella Therapeutics Ltd against its peers.
Discuss the investment returns and shareholder value creation
comparing Arovella Therapeutics Ltd with its peers.
Analyze the financial leverage
of Arovella Therapeutics Ltd compared to its main competitors.
Show all profitability ratios
for Arovella Therapeutics Ltd.
Provide ROE
for Arovella Therapeutics Ltd.
Provide ROA
for Arovella Therapeutics Ltd.
Provide ROIC
for Arovella Therapeutics Ltd.
Provide ROCE
for Arovella Therapeutics Ltd.
Provide Gross Margin
for Arovella Therapeutics Ltd.
Provide Operating Margin
for Arovella Therapeutics Ltd.
Provide Net Margin
for Arovella Therapeutics Ltd.
Provide FCF Margin
for Arovella Therapeutics Ltd.
Show all solvency ratios
for Arovella Therapeutics Ltd.
Provide D/E Ratio
for Arovella Therapeutics Ltd.
Provide D/A Ratio
for Arovella Therapeutics Ltd.
Provide Interest Coverage Ratio
for Arovella Therapeutics Ltd.
Provide Altman Z-Score Ratio
for Arovella Therapeutics Ltd.
Provide Quick Ratio
for Arovella Therapeutics Ltd.
Provide Current Ratio
for Arovella Therapeutics Ltd.
Provide Cash Ratio
for Arovella Therapeutics Ltd.
What is the historical Revenue growth
over the last 5 years for Arovella Therapeutics Ltd?
What is the historical Net Income growth
over the last 5 years for Arovella Therapeutics Ltd?
What is the current Free Cash Flow
of Arovella Therapeutics Ltd?
Discuss the annual earnings per share (EPS)
trend over the past five years for Arovella Therapeutics Ltd.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
AU |
![]() |
Arovella Therapeutics Ltd
ASX:ALA
|
106.5m AUD | -15.1 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
730.4B USD | 35.3 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
364B USD | 12.2 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK | 13.5 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
209B CHF | 9.5 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
186.9B CHF | 10.6 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
161.1B GBP | 130.8 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
201.7B USD | 8.6 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD | 261.3 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
136.6B USD | 7.5 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
AU |
![]() |
Arovella Therapeutics Ltd
ASX:ALA
|
Average EV/EBITDA:
433.6
|
N/A | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
35.3
|
30%
|
1.2 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
12.2
|
7%
|
1.7 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
13.5
|
13%
|
1 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
9.5
|
5%
|
1.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
10.6
|
5%
|
2.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
130.8
|
10%
|
13.1 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
8.6
|
8%
|
1.1 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
261.3
|
N/A | N/A |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
7.5
|
2%
|
3.7 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.